FCCC LOGO Faculty Publications
Systemic therapy for bladder cancer finally comes into a new age
Future Oncol. 2016 Oct;12(19) :2227-42
PMID: 27402371    PMCID: PMC5066115    URL: https://www.ncbi.nlm.nih.gov/pubmed/27402371
Back to previous list
Abstract
Systemic therapy for bladder cancer, both localized muscle-invasive disease and metastatic disease, has seen minimal progress over the past two decades. Current approaches rely upon cytotoxic chemotherapy combinations aimed at increasing cure rates or achieving palliation and disease control, but these regimens are fraught with short- and long-term toxicities and outcomes remain suboptimal. The emergence of systemic immunotherapies that can provide durable remissions in subsets of patients with other malignancies has the potential to transform the field, and early phase trials have begun to demonstrate activity in some patients with metastatic bladder cancer. In this article, we review the current state of systemic therapy for bladder cancer and discuss the current literature and ongoing trials utilizing various immunotherapies.
Notes
Zibelman, Matthew Plimack, Elizabeth R eng P30 CA006927/CA/NCI NIH HHS/ Review England 2016/07/13 06:00 Future Oncol. 2016 Oct;12(19):2227-42. doi: 10.2217/fon-2016-0135. Epub 2016 Jul 12.